ArticleCancers2025
Optimizing Outcomes in Breast Reconstruction: The Role of Hormonal Therapy Management.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer comprises diverse subtypes with prognostic and therapeutic implications. Hormone therapy plays a crucial role in managing tumors expressing hormonal receptors, but its impact on breast reconstruction outcomes remains unclear. This study aims to evaluate the association between perioperative hormone therapy continuation and the incidence of postoperative complications following breast reconstruction (including autologous, prosthetic, and hybrid techniques), with a focus on identifying specific complication types to refine patient management strategies.
methodsA retrospective analysis was conducted on patients who underwent breast reconstruction following mastectomy for hormone receptor-positive breast cancer. Patients were categorized based on the appropriate discontinuation of hormonal therapy. Clinical data, including patient characteristics, treatment regimens, and complication occurrences, were registered and analyzed.
resultsInadequate suspension of hormonal therapy during the perioperative period was significantly associated with a higher rate of complications, particularly in the immediate and early phases. Complications such as skin alterations, flap failure, seroma development, and clinical infection showed significant associations with the continuation of hormone therapy (
conclusionsPreliminary findings suggest a potential correlation between the continuation of hormone therapy during the perioperative phase and the development of complications following breast reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.